Given the pronounced upregulation of SAE2 and sumoylated proteins in MCL and their necessity for MCL cell survival, we next wanted to know if targeting SAE2 with a clinical grade small molecule inhibitor would lead to anti-tumor activity in MCL. Here, UBA2 is linked to neoplasm.